Key Highlights

  • Appointment adds experienced commercial leadership to the board.
  • Enhances oversight of audit and compensation matters.
  • Supports continued development of the POZ platform and SER‑252 program.

Serina Therapeutics, Inc. (NYSE American: SER) announced that Farrell Simon, Pharm.D. Has been appointed to its Board of Directors, with his service beginning in July 2026. Simon will serve on both the Audit Committee and the Compensation Committee, providing the board with additional depth in commercialization strategy and financial oversight.

Board Appointment

The board’s composition is being refreshed to align with the company’s goal of advancing its POZ platform. Simon’s experience in biotech commercialization is expected to strengthen the board’s ability to guide the company through upcoming partnership and financing activities. The addition reflects Serina’s ongoing commitment to strong governance and strategic execution.

Executive Background

Farrell Simon brings a blend of experience from the biotechnology and pharmaceutical sectors. Prior to his current role, Simon spent a significant portion of his career at a major pharmaceutical company, holding senior positions focused on market access, product launch, and strategic planning.

Market Context

The appointment arrives as Serina continues to position its POZ platform for further development and potential collaborations. While the stock has been managing its historical price range, the board refresh is viewed by analysts as a positive step toward operational maturity. The broader biotechnology sector has seen varied performance, with companies focusing on novel delivery platforms gaining particular attention.

Upcoming Catalyst

The next material event for Serina is the SER‑252‑1b trial, a Phase 1b study designed to evaluate safety, tolerability, and pharmacokinetics in patients with Parkinson’s disease. Detailed objectives for the trial are outlined in the SER‑252 Registrational Study Design Overview. Results from this trial are expected later in the year and will provide critical insight into the POZ‑apomorphine candidate’s clinical profile.

Regulatory Filing

Based on the Form 8‑K filed July 2026.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.